Q-omics provides the consensus-scored SCG5 profile across patient tissues and cancer cell-line models. SCG5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SCG5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SCG5 RNA expression shows 15,786 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where SCG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCG5 survival associations across molecular data types. SCG5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCG5 RNA expression–survival associations across cancer types. High SCG5 expression shows unfavorable associations in HNSC, KIRC, KICH, UCS and GBM, but favorable associations in THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SCG5 RNA expression.
This table summarizes SCG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SCG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCG5 shows higher tumor expression in HNSC, LUAD, THCA, KIRP, LUSC and BLCA. The HNSC box plot shows higher SCG5 RNA expression in tumor versus normal tissue (log2 FC = +1.635, t-test p < 0.001).
This table shows molecular features associated with SCG5 in patient tissues and cancer cell lines. In patient samples, SCG5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SCG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
